Results and Impact of a Patient-Reported Symptoms Tool in Multiple Myeloma

A comprehensive analysis of the phase 1 LEGEND-2 study shows a correlation between cytokine release syndrome and coagulation disorders inpatient with multiple myeloma treated with CAR T cells.

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

Douglas Sborov, MD, MS, discusses and compares the many triplet therapies for patients who show disease progression after several lines of therapy in this first article of a 2 part series.

The FDA has approved avapritinib for adult patients with indolent systemic mastocytosis based on findings from the phase 2 PIONEER trial.

A phase 3 trial evaluating roxadustat for the treatment of anemia in patients receiving concurrent chemotherapy for non-myeloid malignancies met its primary end point.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.